Skip to content

Search

Showing results for "1"

Healthway Kimberly Compassion

In this project, we aim to understand how mindfulness, compassion, and related constructs are experienced by Aboriginal people in the Kimberley region of Western Australia.

Impact of Repeat Pertussis Vaccination on Infant and Maternal Antibody Quality

Ruth Peter Thornton Richmond PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Head, Vaccine Trials Group

Junk-food filled neighbourhoods: Building a local evidence-base for change’. Rapid Obesity Policy Translation Program

Gina Trapp BHSc(Hons1A), RPHNutr, PhD Honorary Research Associate Gina.Trapp@thekids.org.au ARC DECRA Fellow & Head of Food and Nutrition Research Dr

Mitochondrial Gene Therapy

Aleksandra Filipovska FAA, FAHMS BSc PhD Louis Landau Chair in Child Health Research; NHMRC Leadership Fellow; Deputy Director, ARC Centre of

From Diagnosis to Consumer Representative – Danae’s journey to making a difference

Recognising the signs of type 1 diabetes (T1D) can be tricky. Often put down to growing pains, a virus or “something going around”, a diagnosis can take some time if children aren’t severely sick and attend an emergency department.

Embrace Big Idea 2023 Winner

Congratulations to our Rio Tinto Children's Diabetes Centre mental health and wellbeing team who, in partnership with the Embrace childhood trauma

Sleepovers and diabetes

Love them or hate them, but sleepovers are a popular pastime for children. Understandably, parents of children living with type 1 diabetes might be hesitant to leave them in someone else’s care for an extended period, but there are ways to ensure that everyone is prepared for a safe experience.

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade

W. Joost Ben Lizeth Rachael Tao Omar Lesterhuis Wylie Orozco Morales Zemek Wang Elaskalani BSc PhD BSc, MSc, PhD BSc (Hons), PhD PhD BSc, MSc, PhD

Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of age

From 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates.